Dasatinib

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Transitional Cell Carcinoma of the Bladder

Conditions

Transitional Cell Carcinoma of the Bladder

Trial Timeline

Jun 1, 2008 → Dec 1, 2012

NCT ID

NCT00706641

About Dasatinib

Dasatinib is a pre-clinical stage product being developed by Bristol Myers Squibb for Transitional Cell Carcinoma of the Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT00706641. Target conditions include Transitional Cell Carcinoma of the Bladder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00454753	Pre-clinical	Completed	—	—	—
NCT04115059	Phase 1	Terminated	Nov 4, 2019	Dec 31, 2021	Waldenstrom Macroglobulinemia
NCT02297139	Phase 2	Completed	Jul 31, 2015	May 15, 2022	Multiple Indications Cancer
NCT02546791	Pre-clinical	Completed	Jul 22, 2015	Mar 29, 2017	Leukemia
NCT02428855	Phase 2	Completed	Apr 1, 2015	Feb 1, 2018	Cholangiocarcinoma
NCT01850004	Phase 2	Completed	Jan 22, 2014	Oct 8, 2021	Chronic Phase Chronic Myeloid Leukemia
NCT01471106	Phase 2	Completed	Jan 21, 2014	May 30, 2024	Breast Cancer
NCT02389972	Pre-clinical	Completed	Apr 11, 2013	Jul 13, 2017	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
NCT01802450	Phase 2	UNKNOWN	Mar 1, 2013	Dec 1, 2016	Chronic Myeloid Leukemia
NCT01660906	Approved	Completed	Dec 1, 2012	Oct 1, 2015	Chronic Phase Chronic Myeloid Leukemia
NCT01514864	Phase 2	Terminated	May 31, 2012	Jul 23, 2014	Carcinoma, Non-small Cell Lung
NCT01460160	Phase 2	Completed	Apr 13, 2012	Jun 1, 2021	Leukemia, Pediatric
NCT01092728	Phase 2	Terminated	Mar 1, 2011	Aug 1, 2014	Melanoma
NCT00918463	Phase 2	Terminated	Jun 1, 2009	May 23, 2011	Diffuse Large B-cell Lymphoma
NCT00777036	Phase 2	Completed	Mar 20, 2009	Jan 27, 2025	Leukemia
NCT00858403	Phase 2	Terminated	Mar 1, 2009	Jul 1, 2010	Lung Cancer
NCT00764309	Phase 1/2	Completed	Jan 1, 2009	Apr 1, 2011	Scleroderma
NCT00787267	Phase 2	Terminated	Sep 1, 2008	Jun 1, 2013	Non Small Cell Lung Cancer
NCT00706641	Pre-clinical	Completed	Jun 1, 2008	Dec 1, 2012	Transitional Cell Carcinoma of the Bladder
NCT00652574	Phase 1	Completed	Mar 12, 2008	Oct 7, 2022	Malignant Pleural Mesothelioma

Competing Products

20 competing products in Transitional Cell Carcinoma of the Bladder

See all competitors

Product	Company	Stage	Hype Score
Enfortumab vedotin	Astellas Pharma	Phase 2	52
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine	Astellas Pharma	Phase 1/2	41
Pemetrexed + Gemcitabine + Platinol	Eli Lilly	Phase 1/2	41
Vepugratinib + EV + Pembrolizumab	Eli Lilly	Phase 3	77
durvalumab and tremelimumab	AstraZeneca	Phase 2	52
Docetaxel + vandetanib + Placebo	AstraZeneca	Phase 2	52
MK-3475 and BCG	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Everolimus + Everolimus + Paclitaxel	Novartis	Phase 2	52
Buparlisib	Novartis	Phase 2	52
BEZ235	Novartis	Phase 2	52
Atezolizumab	Roche	Phase 3	77
Gemcitabine + Cisplatin + Sunitinib Malate	Pfizer	Phase 2	51
Nivolumab/Ipilimumab	Bristol Myers Squibb	Phase 2	51
vinflunine and best supportive care	Bristol Myers Squibb	Phase 3	76
vinflunine	Bristol Myers Squibb	Phase 2	51
Docetaxel + Oxaliplatin	Sanofi	Phase 2	51
Cabazitaxel	Sanofi	Phase 2/3	64
Rogaratinib (BAY1163877) + Chemotherapy	Bayer	Phase 2/3	62
CG0070 Adenovirus Vector	CG Oncology	Phase 2/3	62

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved